Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29873567 | 0.87 | MAPT (0.44) | MAPTSMN1; SMN2CNR2ACHEKMT2A | |
| SCHEMBL1593005 | 0.83 | MAPT (0.51) | MAPTSMN1; SMN2KAT2BCNR2ACHE | |
| SCHEMBL29872415 | 0.82 | PDE1B (0.40) | MAPTSMN1; SMN2CNR2CNR1PDE1B | |
| SCHEMBL1593522 | 0.80 | CNR2 (0.50) | MAPTSMN1; SMN2KAT2BCNR2ACHE | |
| SCHEMBL25227436 | 0.77 | KMT2A (0.49) | MAPTSMN1; SMN2KAT2BCNR2KMT2A | |
| SCHEMBL30473818 | 0.77 | KMT2A (0.49) | MAPTSMN1; SMN2KAT2BCNR2KMT2A | |
| SCHEMBL1593950 | 0.76 | CNR2 (0.56) | MAPTSMN1; SMN2KAT2BCNR2ACHE | |
| SCHEMBL29872467 | 0.76 | ALDH1A1 (0.46) | MAPTSMN1; SMN2KMT2APDE1BPDE5A | |
| SCHEMBL15556714 | 0.74 | MAPT (0.47) | MAPTSMN1; SMN2NPC1RAB9APDE1B | |
| SCHEMBL23069180 | 0.74 | MAPT (0.50) | MAPTSMN1; SMN2CNR2ACHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | DDR1, DDR2, DDRGK1 | MAPT 3943/4885SMN1; SMN2 1226/4885KAT2B 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.